432 related articles for article (PubMed ID: 25471584)
21. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity.
Sawicka E; Dubois G; Jarai G; Edwards M; Thomas M; Nicholls A; Albert R; Newson C; Brinkmann V; Walker C
J Immunol; 2005 Dec; 175(12):7973-80. PubMed ID: 16339533
[TBL] [Abstract][Full Text] [Related]
22. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
23. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage.
Rolland WB; Lekic T; Krafft PR; Hasegawa Y; Altay O; Hartman R; Ostrowski R; Manaenko A; Tang J; Zhang JH
Exp Neurol; 2013 Mar; 241():45-55. PubMed ID: 23261767
[TBL] [Abstract][Full Text] [Related]
24. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells.
Xie JH; Nomura N; Koprak SL; Quackenbush EJ; Forrest MJ; Rosen H
J Immunol; 2003 Apr; 170(7):3662-70. PubMed ID: 12646631
[TBL] [Abstract][Full Text] [Related]
25. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Johnson TA; Lapierre Y; Bar-Or A; Antel JP
Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
[TBL] [Abstract][Full Text] [Related]
26. FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation.
Mencl S; Hennig N; Hopp S; Schuhmann MK; Albert-Weissenberger C; Sirén AL; Kleinschnitz C
J Neuroimmunol; 2014 Sep; 274(1-2):125-31. PubMed ID: 25081505
[TBL] [Abstract][Full Text] [Related]
27. CXCL5 signaling is a shared pathway of neuroinflammation and blood-brain barrier injury contributing to white matter injury in the immature brain.
Wang LY; Tu YF; Lin YC; Huang CC
J Neuroinflammation; 2016 Jan; 13():6. PubMed ID: 26738635
[TBL] [Abstract][Full Text] [Related]
28. Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720.
Wang F; Tan W; Guo D; He S
Eur J Pharmacol; 2007 Nov; 573(1-3):230-40. PubMed ID: 17716652
[TBL] [Abstract][Full Text] [Related]
29. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
30. FTY720 mitigates torsion/detorsion-induced testicular injury in rats.
Shih HJ; Yen JC; Chiu AW; Chow YC; Pan WH; Wang TY; Huang CJ
J Surg Res; 2015 Jun; 196(2):325-31. PubMed ID: 25862489
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the mode of action of a novel immunosuppressant FTY720 in mice.
Luo ZJ; Tanaka T; Kimura F; Miyasaka M
Immunopharmacology; 1999 Apr; 41(3):199-207. PubMed ID: 10428648
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
33. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
[TBL] [Abstract][Full Text] [Related]
34. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.
Czech B; Pfeilschifter W; Mazaheri-Omrani N; Strobel MA; Kahles T; Neumann-Haefelin T; Rami A; Huwiler A; Pfeilschifter J
Biochem Biophys Res Commun; 2009 Nov; 389(2):251-6. PubMed ID: 19720050
[TBL] [Abstract][Full Text] [Related]
35. FTY720: a most promising immunosuppressant modulating immune cell functions.
Zhang Z; Schluesener HJ
Mini Rev Med Chem; 2007 Aug; 7(8):845-50. PubMed ID: 17692046
[TBL] [Abstract][Full Text] [Related]
36. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
37. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection.
Habicht A; Clarkson MR; Yang J; Henderson J; Brinkmann V; Fernandes S; Jurewicz M; Yuan X; Sayegh MH
J Immunol; 2006 Jan; 176(1):36-42. PubMed ID: 16365393
[TBL] [Abstract][Full Text] [Related]
38. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Johnson TA; Shames I; Keezer M; Lapierre Y; Haegert DG; Bar-Or A; Antel J
Clin Immunol; 2010 Oct; 137(1):15-20. PubMed ID: 20599429
[TBL] [Abstract][Full Text] [Related]
39. Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction.
Thangada S; Shapiro LH; Silva C; Yamase H; Hla T; Ferrer FA
J Urol; 2014 May; 191(5 Suppl):1508-16. PubMed ID: 24679864
[TBL] [Abstract][Full Text] [Related]
40. [Role of T lymphocytes in ischemic brain injury].
Shichita T; Konoeda F; Yoshimura A
Rinsho Shinkeigaku; 2010 Nov; 50(11):878-80. PubMed ID: 21921486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
